Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company ...

Phage-focused BiomX is undergoing a “strategic and financial reset” in efforts to improve its position, mapping out a possible shift from therapeutics to the defense sector.   | Phage-focused BiomX is ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage ...

A new research investment is taking aim at Streptococcus suis, a bacterial pathogen that poses ongoing health and economic ...

Dr. Marisa Azad alleges The Ottawa Hospital failed to act after investigation found she'd been bullied and harassed by male ...

Weizmann Institute researchers have used AI and experimental biology to identify three new families of proteins that viruses ...

Race for new antibiotics intensifies as WHO warns drug pipeline remains thin, and remains structurally unfit to support antibiotic innovation ...

Bacteriophage T7, a virus that preys on E. coli, becomes a more effective killer after spending time aboard the International Space Station, according to new research from University of ...

The genomes of phages - viruses that infect bacteria - are largely composed of "dark matter": genes that encode proteins ...

About BiomX Inc. BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target an ...

Bacteria and the viruses that infect them are perpetually at war. Their deadly clashes push both kinds of microbes to evolve ...